Price regulation of Pharmaceuticals (2)

Respecto al artículo anteriormente comentado, de Marginal Revolution, han surgido multitud de páginas web (realmente blogs en su mayoría), que han venido realizando reflexiones al respecto.
Una de ellas que resalta por su interés es la de Asymmetrical Information, blog de economía leído diariamente por más de 6500 personas.
Una colaboración destaca por su verosimilitud:
Pharmas, on average, spend ~17-18% of sales on R&D, although some companies (especially some of the biotechs) spend 40% or more on R&D. The figure for marketing is ~10-11% of sales (quick calculation on my part; feel free to correct if needed, but please cite your sources).
For more info, check out http://www.cato.org/pubs/pas/pa-475es.html (pdf)
Here's an interesting point: the Cato report says that "Pharmaceutical marketing accounted for $13.8 billion in 1999. Yet more than half of that— $7.2 billion in that year—was for free samples of drugs, which serve as a discount when doctors pass them out to patients."
According to the pharma industry trade group, phrma.org, the industry spent about $22 billion on R&D in 1999. The current figure is ~$33 billion.